Doxazosin Tablets, USP, 4mg, 30-count bottles, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-109-52
Published May 3, 2023 · Recall initiated: March 16, 2023
Summary
FDA records drug Class II recall D-0550-2023, published May 3, 2023 and initiated March 16, 2023. Recalling firm: Northwind Pharmaceuticals LLC; Status: Ongoing; Reported quantity: 33 bottles; Lot: Lot#: F107752201, Exp. Date 05/31/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations
What to do
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get an email if DOXAZOSIN has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- DOXAZOSIN
- Manufacturer
- Northwind Pharmaceuticals LLC
- Distributor
- Nationwide with the United States
- Lot
- Lot#: F107752201, Exp. Date 05/31/2024
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDABusPIRone Hydrochloride Tablets USP, 7.5 mg, 30-count bottles, Rx Only, Repackaged By: NOrthwindMay 3, 2023
- FDAGlimepiride Tablets, USP 2mg, packaged in a) 30-count bottles (NDC 51655-383-52), and b)90-count bottles (NDCMay 3, 2023
- FDADoxazosin Tablets USP 1 mg, Rx Only, Packaged as: a) 100-count bottle NDC 16729-211-01 UPC 3 16729 21101 7; b)March 8, 2023
- FDADoxazosin Tablets USP, 8 mg, Rx Only, Packaged in: a) 100 Tablets NDC 16729-415-01 UPC 3 16729 41501 9; b)March 8, 2023
- FDADoxazosin Tablets USP, 2 mg, Rx Only, Packaged as: a) 100-count bottle NDC 16729-414-01 UPC 3 16729 41401 2;March 8, 2023
- FDADoxazosin Tablets USP, 4 mg, Rx Only, Packaged as: a) 100-count bottle NDC 16729-213-01 UPC 3 16729 21301 1;March 8, 2023
Questions about this recall
Was Doxazosin Tablets, USP, 4mg, 30-count bottles, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-109-52 recalled?
Yes. FDA published recall D-0550-2023 on May 3, 2023. Reported hazard: CGMP Deviations
What should I do if I have this product?
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: DOXAZOSIN.